Premium
Cytokine polymorphisms and hepatocellular carcinoma
Author(s) -
Chung Raymond T.
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20837
Subject(s) - hepatocellular carcinoma , medicine , cirrhosis , genotyping , hepatitis c virus , hepatitis b virus , mandate , liver disease , fibrosis , carcinoma , disease , virus , virology , immunology , genotype , gene , biology , genetics , political science , law
Regardless of whether monitoring practices change as a result of genotyping, the mandate that replicative hepatitis B virus disease must be treated because of the long‐term risk for necroinflammatory disease, fibrosis, cirrhosis, and hepatocellular carcinoma remains firmly in place. See also pages 740–8.